Marcel Leist

Mitogen-activated protein kinase-activated protein kinase 2-deficient mice show increased susceptibility to Listeria monocytogenes infection.

Burning up TNF toxicity for cancer therapy.

Eradication of glioblastoma, and breast and colon carcinoma xenografts by Hsp70 depletion.

Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression.

Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo.

Defined inflammatory states in astrocyte cultures: correlation with susceptibility towards CD95-driven apoptosis.

Improvement of embryonic dopaminergic neurone survival in culture and after grafting into the striatum of hemiparkinsonian rats by CEP-1347.

Lysosomes in cell death.

Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice.

Derivatives of erythropoietin that are tissue protective but not erythropoietic.

Sensitization to the lysosomal cell death pathway upon immortalization and transformation.

Specific modulation of astrocyte inflammation by inhibition of mixed lineage kinases with CEP-1347.

Poly(ADP-ribose) glycohydrolase as a target for neuroprotective intervention: assessment of currently available pharmacological tools.

The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin.

Botulinum neurotoxin C initiates two different programs for neurite degeneration and neuronal apoptosis.

Inhibition of microglial inflammation by the MLK inhibitor CEP-1347.

CEP-11004, an inhibitor of the SAPK/JNK pathway, reduces TNF-alpha release from lipopolysaccharide-treated cells and mice.

Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway.

The inflammatory transcriptome of reactive murine astrocytes and implications for their innate immune function.

Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia.

A role for mixed lineage kinases in granule cell apoptosis induced by cytoskeletal disruption.

Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity.

Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives.

The dynamics of the LPS triggered inflammatory response of murine microglia under different culture and in vivo conditions.

[What can a chair on alternatives to animal experimentation effectuate?].

Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo.

Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures.

Attenuated amyloid-beta aggregation and neurotoxicity owing to methionine oxidation.

Wide spectrum modulation by KP-544 in models relevant for neuronal survival.

Pathological apoptosis in the developing brain.

Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor.

The Sonic hedgehog pathway mediates carbamylated erythropoietin-enhanced proliferation and differentiation of adult neural progenitor cells.

Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels.

Molecular basis for detection of invading pathogens in the brain.

Food for thought... on the real success of 3R approaches.

High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO).

Food for thought ... on the evolution of toxicology and the phasing out of animal testing.

The dawning of a new age of toxicology.

The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapy.

Measurement of cellular beta-site of APP cleaving enzyme 1 activity and its modulation in neuronal assay systems.

The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation.

Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells.

The network formation assay: a spatially standardized neurite outgrowth analytical display for neurotoxicity screening.

Food for thought ... on education in alternative methods in toxicology.

Markers of murine embryonic and neural stem cells, neurons and astrocytes: reference points for developmental neurotoxicity testing.

The Center for Alternatives to Animal Testing - Europe (CAAT-EU): a transatlantic bridge for the paradigm shift in toxicology.

Erythropoietin: not just about erythropoiesis.

Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice.

Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite.

Food for thought ... considerations and guidelines for basic test method descriptions in toxicology.

TLR2 hypersensitivity of astrocytes as functional consequence of previous inflammatory episodes.

Assessment of chemical-induced impairment of human neurite outgrowth by multiparametric live cell imaging in high-density cultures.

Sensitivity of dopaminergic neuron differentiation from stem cells to chronic low-dose methylmercury exposure.

Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line.

Translating neurobehavioural endpoints of developmental neurotoxicity tests into in vitro assays and readouts.

GFAP-independent inflammatory competence and trophic functions of astrocytes generated from murine embryonic stem cells.

Critical evaluation of the use of dogs in biomedical research and testing in Europe.

A framework program for the teaching of alternative methods (replacement, reduction, refinement) to animal experimentation.

Autoproteolytic fragments are intermediates in the oligomerization/aggregation of the Parkinson's disease protein alpha-synuclein as revealed by ion mobility mass spectrometry.

Highlight report: towards the replacement of in vivo repeated dose systemic toxicity testing.

Uncoupling of ATP-depletion and cell death in human dopaminergic neurons.

A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing - t4 report*.

Locally resolved membrane binding affinity of the N-terminus of α-synuclein.

Control of Aβ release from human neurons by differentiation status and RET signaling.

Evaluation of developmental toxicants and signaling pathways in a functional test based on the migration of human neural crest cells.

Autocatalytic nitration of prostaglandin endoperoxide synthase-2 by nitrite inhibits prostanoid formation in rat alveolar macrophages.

Extensive transcriptional regulation of chromatin modifiers during human neurodevelopment.

Compound selection for in vitro modeling of developmental neurotoxicity.

Epigenetic changes and disturbed neural development in a human embryonic stem cell-based model relating to the fetal valproate syndrome.

Characterization of mouse cell line IMA 2.1 as a potential model system to study astrocyte functions.

Novel technologies and an overall strategy to allow hazard assessment and risk prediction of chemicals, cosmetics, and drugs with animal-free methods.

The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans.

Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach.

A 3-dimensional human embryonic stem cell (hESC)-derived model to detect developmental neurotoxicity of nanoparticles.

Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies.

Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice.

Metabolomics in toxicology and preclinical research.

Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice.

Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants.

Monocrotophos in Gandaman village: India school lunch deaths and need for improved toxicity testing.

Generation of genetically-modified human differentiated cells for toxicological tests and the study of neurodegenerative diseases.

A roadmap for hazard monitoring and risk assessment of marine biotoxins on the basis of chemical and biological test systems.

Test systems of developmental toxicity: state-of-the art and future perspectives.

Targeting chelatable iron as a therapeutic modality in Parkinson's disease.

Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells.

Epigenetics and transcriptomics to detect adverse drug effects in model systems of human development.

Instruments for assessing risk of bias and other methodological criteria of animal studies: omission of well-established methods.

Developmental neurotoxicity - challenges in the 21st century and in vitro opportunities.

Acrylamide alters neurotransmitter induced calcium responses in murine ESC-derived and primary neurons.

Identification and affinity-quantification of ß-amyloid and α-synuclein polypeptides using on-line SAW-biosensor-mass spectrometry.

From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects.

Current approaches and future role of high content imaging in safety sciences and drug discovery.

State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology.

Lineage-specific regulation of epigenetic modifier genes in human liver and brain.

Consensus report on the future of animal-free systemic toxicity testing.

Impairment of glutamate signaling in mouse central nervous system neurons in vitro by tri-ortho-cresyl phosphate at noncytotoxic concentrations.

Spatial control of Cdc42 signalling by a GM130-RasGRF complex regulates polarity and tumorigenesis.

Alpha-synuclein binds to the inner membrane of mitochondria in an α-helical conformation.

Toxicogenomics directory of chemically exposed human hepatocytes.

International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes.

Systems Toxicology: The Future of Risk Assessment.

From smoking guns to footprints: mining for critical events of toxicity pathways in transcriptome data.

Prevention of human dopaminergic neurodegeneration in an astrocytes co-culture system allowing endogenous drug metabolism.